October

Despite having a great product, your company can suffer from mistakes made during the product launch. Here are five tips on avoiding the mistakes others have made.

Academia is getting ever more aggressive about helping entrepreneurs get a running start. An emerging crown jewel could well be Stanford University's brand new StartX.

Many would agree that surgeons are qualified to create innovative medical devices that may be superior to what is currently available. But the controversy arises when surgeons begin to profit by purchasing their own products for use in their patients.

At this week's Biotech 2011 conference, speakers from Teva Pharmaceutical Industries and Merck spoke about how biotech companies can survive in this tough regulatory and economic environment.

In the race to get new medical devices to market, companies encounter FDA speed bumps that slow down the process. But would we really be willing to accept the risks that would accompany fast FDA approvals?

Can "boom and bust" cycles exist in the venture funding market? You bet they can. And recent data from the chemical sector is a great example of how and why.

The FDA needs a chief innovation officer to help the agency stay informed about the latest technological advances, says the head of the biotechnology industry's leading trade group. Read more about what he has to say on the FDA and FDA reform.

Does the healthcare business have its own Steve Jobs? Maybe not, but instead there are many individuals and companies doing innovative biotech research.

In a venture funding climate seeking large returns, thousands of potentially successful entrepreneurial startups can't get the financing they need to make a difference in the economy and in the culture. The problem isn't a new one, but it is a damaging one.

There is no shortage of well-educated people in academic environments. But the challenge is in turning the attention of those bright minds to entrepreneurship. Here are a few ideas on how to do it.